Date: 09 May 2008

Is PET always an advantage versus planar and SPECT imaging?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The article by Abass Alavi and Sandip Basu in this issue of the European Journal of Nuclear Medicine and Molecular Imaging vividly embodies, in a scenario that seems to be easy to reach, the expectations that imaging through positron emission tomography (PET) has raised in the nuclear medicine community at large. In Alavi’s view, this scenario resolutely points to soon-to-come wide availability of a complete armamentarium of PET radiopharmaceuticals capable of substituting virtually all of the single photon agents currently employed. Therefore, the most likely horizon that the author depicts for the future of diagnostic nuclear medicine is PET imaging, with dismal chances for both planar imaging and single photon computed tomography (SPECT) to even survive in the daily clinical routine [1].

For envisaging the inescapable evolution from single photon to PET imaging, Alavi presents an exciting compendium of the many routes followed to achieve the long-pursued “dream come true” for nuclear ...

The opinions expressed within the Controversies section represent the views of the authors only. The article arguing for this proposition is published at http://dx.doi.org/10.1007/s00259-008-0813-2